Target intelligence / Profile preview

Mucin-1 (MUC1) antigen (MUC1)

Target: MUC1
Molecular classification: Glycoprotein, Tumor-associated antigen, Cell surface mucin, Other

Overview

Mucin-1 (MUC1) is a high-molecular-weight, type I transmembrane glycoprotein that is abundantly expressed on the apical surface of mucosal epithelial cells. In cancer, MUC1 is often overexpressed and aberrantly glycosylated, leading to exposure of novel epitopes such as the one recognized by the BrE-3 monoclonal antibody. These epitopes are utilized for diagnosis, prognosis, and as targets for therapeutic antibodies and vaccines. BrE-3 is a mouse-derived monoclonal antibody (IgG1) that specifically reacts with a glycosylated epitope on the tandem repeat region of MUC1, a feature exploited in histopathological evaluation and prognosis of breast carcinoma and in preclinical studies of immunotherapy[3][7].

Other names: CD227PEM (polymorphic epithelial mucin)epithelial membrane antigen (EMA)CA15-3 (as a biomarker)milk fat globule membrane antigen

Mechanism of action

Antibody binding to MUC1 to induce immune-mediated tumor cell killing (ADCC, CDC); Blockade of MUC1-mediated immune evasion or signaling

Biological functions

Cell adhesion modulationCell signalingProtection of epithelial cellsImmune evasion (when overexpressed in tumors)Other

Disease associations

Cancer (notably breast, ovarian, pancreatic, and other epithelial cancers)Other

Safety considerations

On-target/off-tumor toxicity due to low-level MUC1 expression on normal epithelial tissuesPotential for immune-related adverse events in immunotherapies

Interacting drugs

Monoclonal antibodies (e.g., BrE-3, AR20.5, SM3, HMFG1/2)

1 more in the full profile.

Biomarkers

MUC1 expression and its serum fragment CA15-3 (breast cancer prognosis and monitoring)BrE-3 epitope staining (prognostic utility in breast cancer)

Beyond the preview

Go deeper on Mucin-1 (MUC1) antigen (MUC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin-1 (MUC1) antigen (MUC1).

Explore the full profile